News | July 01, 2022
H Clinical adds commercial home health capabilities for pharma industry
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
Subscribe To Our Newsletter & Stay Updated
